ARW ON RNA

Leadership, strength-GettyImages-2249283142 Scaling Personalization: Inside The Manufacturing & Analytical Hurdles Of mRNA Cancer Immunotherapies

As we know from the autologous cell therapies that have come before us, manufacturing and scaling personalized products is no mean feat, and there are a handful of efforts we need to be tackling today to realize a more efficient and (ideally) decentralized manufacturing process. Fortunately for us, the panel had a few ideas on what it will take to make our analytical development and manufacturing more efficient processes. 

OUR EXPERT NETWORK

MEET ARW

Anna Rose

I’ve spent the past 10 years building relationships across the biologics and advanced therapies industry. In addition to hosting conversations and writing thought leadership articles, my goal as the editorial and community director for Advancing RNA is to find creative ways for the RNA (and broader ATMP) space to discuss, debate, and ultimately define a mature RNA therapeutics industry.    

Start the conversation by following me on LinkedIn!

EDITORIAL COLLECTIONS

Complex questions in RNA rarely have simple answers. Our Editorial Collections gather essential perspectives in one place, giving you a closer look at the decisions, technologies, and challenges influencing the field.

More Editorial Collections